Trial Profile

Phase 1/2 study of IDE397 monotherapy cohort expansion

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IDE 397 (Primary)
Indications Bladder cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use

07 Nov 2023 According to an IDEAYA Biosciences media release, 8 patients have been dosed in the IDE397 monotherapy expansion in the priority tumor types, and 2 patients have not yet had a first tumor scan assessment, as of the October 13, 2023 cut-off date.
12 Jun 2023 According to an IDEAYA Biosciences media release, monotherapy expansion dose for the Phase 2 has been selected and enrollment is ongoing.
09 May 2023 According to an IDEAYA Biosciences media release, the company continuing to enroll patients in parallel into the monotherapy dose escalation portion of the clinical trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com